Immunoadoptive Cell Therapy Private Limited (ImmunoACT) has received approval from the Central Drug Standards Control Organisation of India for its NexCAR19, a CAR-T therapy, to treat relapsed or refractory B-cell lymphomas and leukemia. This approval makes ImmunoACT the first to bring indigenous CAR-T cell therapy to India. The approval came after a Phase I/II trial of 60 patients showed a 70% overall response rate and significant delay in cancer progression. However, the therapy, which will cost INR 30-40 lakh ($36,000- $48,000), is still unaffordable for many. There are also concerns regarding the availability of specialized facilities and skilled labor for administering the therapy, mostly limited to major cities. ImmunoACT may face future competition from Immuneel Therapeutics’ CAR-T therapy, which is currently in Phase II development. Access to and affordability of critical treatments in India are key challenges in the healthcare sector.
To read more, click here.
[Source: GlobalData, October 31st, 2023]